Abstract 1776P
Background
The global increase in obesity parallels the increase in PCa incidence, but the role of excess weight and weight change throughout adult life and their implications for PCa risk and prognosis are still under debate. We studied whether pre-diagnostic body mass index (BMI) and weight change is linked to PCa risk and prognosis.
Methods
A total of 16 879 healthy men were included to study PCa risk and prognosis in the Prostate Cancer Study throughout life (PROCA-life), based on those who participated in the prospective cohort Tromsø Study (1994-2016). Pre-diagnostic BMI and weight change (relative weight change in percent of baseline weight between two waves of the Tromsø study) during follow-up were measured. Detailed information from histopathological and clinical medical records for PCa cases were obtained. Cox proportional hazard and logistic regression models were used to estimate hazard ratios (HRs) and odds ratios (ORs) for the associations between pre-diagnostic measurements of BMI and weight change during follow-up, and PCa risk and overall and PCa specific mortality. Regression models were used to evaluate incidence rate ratios (IRR).
Results
Overall, the participants had a median age at study entry of 44 years, 46.0% were overweight and 13.8% were obese. In total 904 men developed PCa during follow-up, with a median age at diagnosis of 68 years. The incidence rates for PCa increased from 1995 to 2019 (overall IRR 2.27, 95% CI 1.82-2.83). We observed that men with a pre-diagnostic BMI ≥ 30kg/m2 at study entry, and who had a weight gain > 5% during follow-up, had a three-fold increased risk for incident PCa (HR 2.94, 95% CI 1.36-6.36). Overweight was associated with lower Gleason grade (OR 0.64, 95% CI 0.43-0.96) and lower Prostate Specific Antigen (OR 0.69, 95% CI 0.48-0.99). Overall, 311 PCa cases died, of whom 154 was PCa related deaths (17%). Pre-diagnostic obesity was associated with PCa-specific death (HR 1.73, 95% CI 1.03-2.91).
Conclusions
Our observation that weight gain in adult pre-diagnostic obese men was associated with increased risk for incident PCa, and that pre-diagnostic obesity increased the risk of PCa-mortality, support the importance to combat excess weight gain in the general population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Data protection office at University Hospital of North-Norway (UNN).
Funding
University of Tromsø.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1239P - NHS-Galleri trial enrolment approaches and participant sociodemographic diversity
Presenter: Charles Swanton
Session: Poster session 14
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14